NCT05578846 - Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Healthy Adult Participants

Interventions

DRUG

Treatment A

Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.

DRUG

Treatment B

Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.

DRUG

Treatment C

Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.

Trial Locations (1)

Research Site, Baltimore